Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Corcept Therapeutics
Parabilis Medicines, Inc.
Genmab
Alliance Foundation Trials, LLC.
AstraZeneca
Whitehawk Therapeutics, Inc.
AstraZeneca
Sichuan Baili Pharmaceutical Co., Ltd.
Eli Lilly and Company
Yonsei University